Abstract

KCI requests funds for five Program Leaders and seven Program Co-Leaders. These individuals and their respective roles and responsibilities are described in detail within each Program narrative: 1) Breast Cancer Biology Program, Section 8.0.1;2) Developmental Therapeutics Program, Section 8.0.2;3) Molecular Biology and Genetics Program, Section 8.0.3;4) Population Studies and Disparities Research, Section 8.0.4;and 5) Proteases and Cancer Program, Section 8.0.5.

Public Health Relevance

Five Program Leaders and seven Program Co-Leaders provide leadership to each of the five scientific Programs by developing and implementing strategic planning for the Programs, facilitating intra- and interprogrammatic interactions, leading Program meetings, mentoring junior faculty, and advocating for shared resource facilities.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-30
Application #
8380954
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-01-09
Budget End
2012-11-30
Support Year
30
Fiscal Year
2012
Total Cost
$120,634
Indirect Cost
$41,269

  Institution

Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202

  Publications

Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203
Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Heath, Elisabeth I; Lynce, Filipa; Xiu, Joanne et al. (2018) Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res 38:2235-2240
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963

Showing the most recent 10 out of 826 publications